208 related articles for article (PubMed ID: 30910278)
21. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
22. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy in dyslipidemia: where are we now?
Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
[TBL] [Abstract][Full Text] [Related]
24. Lipids: a personal view of the past decade.
Katsiki N; Mikhailidis DP
Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
[TBL] [Abstract][Full Text] [Related]
25. [Not Available].
Barthelmes J; Sudano I
Praxis (Bern 1994); 2017 Aug; 106(17):933-940. PubMed ID: 28830329
[No Abstract] [Full Text] [Related]
26. Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies.
Ali AH; Younis N; Abdallah R; Shaer F; Dakroub A; Ayoub MA; Iratni R; Yassine HM; Zibara K; Orekhov A; El-Yazbi AF; Eid AH
Curr Med Chem; 2021; 28(36):7427-7445. PubMed ID: 33655822
[TBL] [Abstract][Full Text] [Related]
27. Ongoing challenges for pharmacotherapy for dyslipidemia.
Pisaniello AD; Scherer DJ; Kataoka Y; Nicholls SJ
Expert Opin Pharmacother; 2015 Feb; 16(3):347-56. PubMed ID: 25476544
[TBL] [Abstract][Full Text] [Related]
28. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
29. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering treatment in peripheral artery disease.
Katsiki N; Giannoukas AD; Athyros VG; Mikhailidis DP
Curr Opin Pharmacol; 2018 Apr; 39():19-26. PubMed ID: 29413998
[TBL] [Abstract][Full Text] [Related]
31. What is new in lipid-lowering therapies in diabetes?
Cheung YM; O'Brien R; Ekinci EI
Intern Med J; 2019 Dec; 49(12):1472-1480. PubMed ID: 30887650
[TBL] [Abstract][Full Text] [Related]
32. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Nakamura M; Uno K; Hirayama A; Ako J; Nohara A; Arai H; Harada-Shiba M
BMJ Open; 2017 Jul; 7(6):e014427. PubMed ID: 28674132
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Bilz S
Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
[No Abstract] [Full Text] [Related]
34. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
35. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
36. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
37. [ECS guidelines 2016 - dyslipidaemias].
Sinning D; Landmesser U
Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
[TBL] [Abstract][Full Text] [Related]
38. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
39. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Agrawal S; Zaritsky JJ; Fornoni A; Smoyer WE
Nat Rev Nephrol; 2018 Jan; 14(1):57-70. PubMed ID: 29176657
[TBL] [Abstract][Full Text] [Related]
40. [Dyslipidemias : Diagnostics and management].
Sinning D; Landmesser U
Herz; 2017 Sep; 42(6):607-620. PubMed ID: 28791432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
